ATOR 4066
Alternative Names: ATOR-4066; Neo-X-PrimeLatest Information Update: 20 Nov 2025
At a glance
- Originator Alligator Bioscience
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; CEACAM5 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Nov 2025 Pharmacodynamics data from preclinical trial in Solid tumours released by Alligator Bioscience
- 30 Oct 2024 ATOR 4066 is still in preclinical development in Solid-tumours in Sweden (Parenteral)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in Sweden (Parenteral)